Gut Microbiome Study

A clinical trial looking at constipation and gut dysfunction is now underway at the University of Queensland under the guidance of A/professor John O’Sullivan. The purpose of this study is to determine the effectiveness of a prebiotic medication for the treatment of constipation in people with Parkinson’s Disease.

This trial will evaluate the efficacy of prioritised repurposed drugs as promising disease-modifying treatments for Parkinson’s disease. These drugs have been shortlisted by the Cure Parkinson’s Trust Linked Clinical Trials (LCT) program and have been rigorously evaluated for their potential to slow or halt the progression of the disease.

Phase II clinical trials will be conducted at major Queensland hospitals and clinical research centres. We will be recruiting at multiple clinical trial sites from across Queensland including:

    • Royal Brisbane Hospital and UQ Centre for Clinical Research (UQCCR)
    • Wesley Hospital and Wesley Medical Research
    • Gold Coast University Hospital and Griffith Health Centre

 

QDRI-001 – A Double blind, placebo-controlled , crossover trial of Livaux TM for the treatment of functional constipation in patients with Parkinson’s Disease

The purpose of this study is to determine the effectiveness of a prebiotic medication for the treatment of constipation in people with Parkinson’s Disease.

This study is being conducted across South East Queensland. There will be a total of 50 participants enrolled over approximately three sites. Participant involvement in the trial will last 20 weeks, which will include five visits to the study clinic.

Eligibility

Participants must be:

  1. Male or female aged 25 to 80 (inclusive)
  2. Diagnosed with idiopathic Parkinson’s Disease
  3. Have three or less bowel movement per week.

What to expect

This is a cross over study which means you will receive both the active drug and placebo throughout the study. You will receive either study medication or a placebo (a placebo is a medication with no active ingredients).

Study activities will include:

  • A physical examination – measurement of vital signs (heart rate, and blood pressure), a collection of blood, saliva , urine, and stool samples
  • Undergoing two abdominal X-rays
  • Maintaining a regular food diary
  • Completing a number of Parkinson’s disease assessments at each of the five visits.

The study has been ethically approved by the Royal Brisbane and Women’s Hospital,
RBWH-Ethics@health.qld.gov.au.

If you are interested please contact the clinical trials team below

Centre for Clinical Research – University of Queensland (uq.edu.au)

Senior Clinical Trials Coordinator
Elisabeth Arnold
Email: qdri.research@uq.edu.au

Clinical Trials Coordinator
Helen Woodhouse
Email: qdri.research@uq.edu.au
Tel: 07 3346 5043

SIGN UP FOR EMAIL UPDATES

GET PARKINSON'S RESEARCH NEWS, FOUNDATION UPDATES, INVITATIONS TO EVENTS AND MORE.